Raymond James Financial’s Celularity CELU Stock Holding History

Raymond James Financial’s Portfolio CELU Stock Details CELU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-100	Closed	-$196	–	5268
2025 Q2	$196	Buy	+100	New	+$182	﹤0.01%	6784

Other funds holding CELU

CVSC

C.V. Starr & Co New York $192M AUM 35.69% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

YAG

Yorkville Advisors Global Mountainside, New Jersey $155M AUM 58.46% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

HWM

HB Wealth Management Atlanta, Georgia $17.8B AUM 24.16% 1-Year Est. Return

Raymond James Financial's CELU Position: Q3 2025 in Review

Raymond James Financial sold out of Celularity (CELU) in Q3 2025, closing a stake of 100 shares — an estimated $196 sold.

Raymond James Financial first reported a position in CELU in Q2 2025 and held it in 1 quarter. The position peaked at $196 in Q2 2025. 38 funds tracked by Wall St. Rank hold CELU as of Q3 2025.

Raymond James Financial reported no remaining Celularity position as of Q3 2025 after selling out during the quarter.
Raymond James Financial sold 100 Celularity shares in Q3 2025, an estimated $196.
Raymond James Financial first reported a position in Celularity in Q2 2025 and held it in 1 quarter.
Raymond James Financial's Celularity position peaked at $196 in Q2 2025.
38 funds tracked by Wall St. Rank held Celularity as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.